AVROBIO President & CEO Geoff MacKay tellsThe Business of Biotechabout the technology his company is using to drive at-scale gene therapy production for lysosomal disorders, and how they overcame a major manufacturing investment that didn't quite work as planned. Listen now and subscribe so you never miss an episode.
White Paper |
By Geetha Yadav and Ning Liu,Bio-Rad Laboratories, Inc.
Stain-free technology, a technology that existed in principle since early 2000 but was only commercialized in 2010 has changed the protein separation and analysis landscape in the past few years. This article focuses on how protein visualization is accomplished using stain-free technology, its advantages and concerns as well as how stain-free technology can change the way we carry out protein separation and analysis.
Spray-dried amorphous solid dispersions (ASDs) show enormous promise in the delivery of drug compounds with low solubility. A novel platform expands the utility of this approach to meet patient needs.
Pediatric drug development requires a formulation designed to fit the specific needs of that patient population. Not considering these requirements early enough could add significant delays.
A recent study by the Tufts Center for the Study of Drug Development (CSDD) compared cycle times and development economics between multi- and single-source CDMO models.
Gain insight into how practical implementation of innovative technologies and solutions such as multi-attribute method, modernized cell line development workflow using high-yield cell lines and automated systems, as well as next generation purification resins help to accelerate biologics development and commercialization.
